QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: The Marketing Authorisation Holder's Role During an EMA Referral

Test your understanding of the concepts covered by What Does the Marketing Authorisation Holder Do During an EMA Referral?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should an MAH prepare contingency scenarios before the referral outcome is known?

To implement restrictions before they become legally operative To assess operational consequences of possible outcomes without treating them as final requirements To influence the committee by presenting scenarios as predetermined To avoid updating plans after the actual decision

Question 2 of 10 Spontaneous reports do not provide a reliable denominator for an incidence calculation requested by the regulator. What should the MAH do?

Calculate an exact incidence using an assumed denominator without qualification Decline to discuss the issue because the requested analysis is impossible Explain the limitation, describe available data, assess whether a valid alternative exists and state the resulting uncertainty Use the number of reports as the incidence rate

Question 3 of 10 Which principle best captures the article's approach to internal referral governance?

EU legislation prescribes a universal internal referral organisational chart Only Pharmacovigilance and Regulatory Affairs should participate The MAH should control work and accountability while choosing an organisation appropriate to its circumstances Senior management should approve every technical analysis personally

Question 4 of 10 If the regulator reaches a different scientific conclusion from the MAH, which interpretation is most consistent with the article?

The disagreement automatically proves a pharmacovigilance-system failure The MAH has failed unless its recommendation is adopted The difference may reflect scientific disagreement and should be assessed separately from the quality and integrity of the MAH's process The MAH should withdraw all evidence supporting its original assessment

Question 5 of 10 Which response-planning approach is most likely to produce a decision-useful submission?

Start with the company's historical safety narrative and add the committee's questions later Build a question-by-question plan linking each question to evidence, analysis, limitations, conclusion and regulatory implication Submit every available dataset regardless of relevance Allow each function to answer the questions independently without integration

Question 6 of 10 Which activity best reflects the QPPV's post-referral responsibility?

Assume that the referral outcome concerns only the affected product and has no system implications Assess what the referral reveals about the PV system's ability to detect, evaluate, communicate and act on emerging risks Approve all manufacturing implementation activities personally Replace routine signal management with referral-specific monitoring permanently

Question 7 of 10 Where an oral explanation is permitted, what is its proper function?

To replace weaknesses in the written scientific submission with advocacy To introduce unsupported claims that were absent from the dossier To clarify material remaining issues, evidence, limitations, uncertainty and proportionality of the proposed response To negotiate a commercial settlement with the committee

Question 8 of 10 What is the main purpose of reconstructing the safety evidence base before arguing for a regulatory conclusion?

To establish a shared and current basis that distinguishes known facts, inferences, uncertainties and recommendations To identify only evidence that supports the MAH's preferred outcome To replace the committee's assessment with the company's historical assessment To avoid involving medical or epidemiological specialists

Question 9 of 10 A company prefers a targeted risk-minimisation measure over a broad restriction. How should that preference be handled?

The preferred measure should determine which evidence is included The company should distinguish evidence, interpretation, uncertainty, regulatory options and its preferred position The company should present the preferred measure as the committee's likely decision Commercial consequences should be excluded from all internal planning

Question 10 of 10 Why must the MAH verify the designated regulatory contact and communication route for the individual referral?

Because the applicable contact mechanism and procedural consequences can vary by procedure Because only external consultants may receive EMA correspondence Because internal contacts have no role after referral initiation Because the committee communicates only through informal telephone discussions

QPPV.com

Knowledge Assessment: The Marketing Authorisation Holder's Role During an EMA Referral

Cookie Settings